No black box warning on record for Vizimpro

As of the latest FDA labeling reviewed, Vizimpro (DACOMITINIB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Vizimpro medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Interstitial Lung Disease (ILD): Permanently discontinue VIZIMPRO if ILD is confirmed. ( 5.1 ) • Diarrhea: Withhold and reduce the dose of VIZIMPRO based on the severity. ( 2.3 , 5.2 ) • Dermatologic Adverse Reactions: Withhold and reduce the dose of VIZIMPRO based on the severity. ( 2.3 , 5.3 ) • Embryo-Fetal Toxicity: VIZIMPRO can cause fetal harm. Advise females of

No black box warning on record for Vizimpro

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Interstitial Lung Disease (ILD): Permanently discontinue VIZIMPRO if ILD is confirmed. ( 5.1 ) • Diarrhea: Withhold and reduce the dose of VIZIMPRO based on the severity. ( 2.3 , 5.2 ) • Dermatologic Adverse Reactions: Withhold and reduce the dose of VIZIMPRO based on the severity. ( 2.3 , 5.3 ) • Embryo-Fetal Toxicity: VIZIMPRO can cause fetal harm. Advise females of

Vizimpro Black Box Warning

No black box warning on record for Vizimpro

Other warnings & precautions

Vizimpro Black Box Warning

No black box warning on record for Vizimpro

Other warnings & precautions